Burke Internal Medicine & Research

Burke, Virginia 22105

1 studies enrolling now · 16 studies all time

What they study most

Arthritis, Rheumatoid, Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Nephropathy, Dyslipidemia, Heterozygous Familial Hypercholesterolemia, Resistant Hypertension, Type 2 Diabetes, Type 2 Diabetes Mellitus, Type2 Diabetes

Studies at this site

• HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes — Recruiting now
• A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes — Completed
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease — Running, not enrolling
• Gan & Lee Insulin Glargine Target Type (1) Evaluating Research — Completed
• A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety — Completed
• Gan & Lee Insulin Glargine Target Type (2) Evaluating Research — Completed
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk — Completed
• Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen — Completed
• Cardiovascular Inflammation Reduction Trial — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM — Completed
• A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia — Completed
• A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy — Completed
• Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus — Completed